Cargando…
ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy
In the growing therapeutic armamentarium for heart failure (HF) management, vericiguat represents an innovative therapeutic option. The biological target of this drug is different from that of other drugs for HF. Indeed, vericiguat does not inhibit neuro-hormonal systems overactivated in HF or sodiu...
Autores principales: | Di Fusco, Stefania Angela, Alonzo, Alessandro, Aimo, Alberto, Matteucci, Andrea, Intravaia, Rita Cristina Myriam, Aquilani, Stefano, Cipriani, Manlio, De Luca, Leonardo, Navazio, Alessandro, Valente, Serafina, Gulizia, Michele Massimo, Gabrielli, Domenico, Oliva, Fabrizio, Colivicchi, Furio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194817/ https://www.ncbi.nlm.nih.gov/pubmed/37213802 http://dx.doi.org/10.1093/eurheartjsupp/suad106 |
Ejemplares similares
-
ANMCO position paper on the management of hypercholesterolaemia in patients with acute coronary syndrome
por: De Luca, Leonardo, et al.
Publicado: (2023) -
ANMCO position paper ‘Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation’
por: Mocini, David, et al.
Publicado: (2022) -
ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure
por: Di Tano, Giuseppe, et al.
Publicado: (2021) -
ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes
por: De Luca, Leonardo, et al.
Publicado: (2022) -
ANMCO position paper: 2022 focused update of appropriate use criteria for multimodality imaging: aortic valve disease
por: Nardi, Federico, et al.
Publicado: (2022)